JP2005502585A - 治療的核酸の送達を増強するための方法 - Google Patents

治療的核酸の送達を増強するための方法 Download PDF

Info

Publication number
JP2005502585A
JP2005502585A JP2002557425A JP2002557425A JP2005502585A JP 2005502585 A JP2005502585 A JP 2005502585A JP 2002557425 A JP2002557425 A JP 2002557425A JP 2002557425 A JP2002557425 A JP 2002557425A JP 2005502585 A JP2005502585 A JP 2005502585A
Authority
JP
Japan
Prior art keywords
administration
subject
nucleic acid
virus
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002557425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502585A5 (enExample
Inventor
ジェイムズ ジー． バーソウム，
マイケル パー，
スティーブン イー． ファウェル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2005502585A publication Critical patent/JP2005502585A/ja
Publication of JP2005502585A5 publication Critical patent/JP2005502585A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2002557425A 2001-01-22 2002-01-22 治療的核酸の送達を増強するための方法 Pending JP2005502585A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26341601P 2001-01-22 2001-01-22
PCT/US2002/001797 WO2002056918A2 (en) 2001-01-22 2002-01-22 Method of enhancing delivery of a therapeutic nucleic acid

Publications (2)

Publication Number Publication Date
JP2005502585A true JP2005502585A (ja) 2005-01-27
JP2005502585A5 JP2005502585A5 (enExample) 2005-12-22

Family

ID=23001688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002557425A Pending JP2005502585A (ja) 2001-01-22 2002-01-22 治療的核酸の送達を増強するための方法

Country Status (13)

Country Link
US (1) US7534424B2 (enExample)
EP (1) EP1363676B1 (enExample)
JP (1) JP2005502585A (enExample)
AT (1) ATE357935T1 (enExample)
AU (1) AU2002237910B2 (enExample)
CA (1) CA2435443A1 (enExample)
CY (1) CY1106676T1 (enExample)
DE (1) DE60219142T2 (enExample)
DK (1) DK1363676T3 (enExample)
ES (1) ES2283524T3 (enExample)
NZ (1) NZ527645A (enExample)
PT (1) PT1363676E (enExample)
WO (1) WO2002056918A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011074564A1 (ja) * 2009-12-15 2011-06-23 タカラバイオ株式会社 アデノウイルスベクターの製造方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696423B1 (en) * 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
JP4736413B2 (ja) * 2004-12-14 2011-07-27 富士ゼロックス株式会社 生体分子保持物及び生体分子の保存方法
US20140141065A1 (en) * 2012-11-19 2014-05-22 Discovery Genomics, Inc. Method to achieve extended expression of dna infused into liver

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
DE19525900C1 (de) * 1995-07-15 1996-12-12 Max Planck Gesellschaft Leberspezifischer Adenovirus-Expressionsvektor
NZ503401A (en) * 1997-08-29 2003-01-31 Biogen Inc Use of interferon-beta (IFN-B) genes for the treatment of cancer
US6696423B1 (en) * 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
WO2001060377A2 (en) * 2000-02-17 2001-08-23 Genzyme Corporation Methods for treatment of lysosomal storage diseases using biphosphonates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011074564A1 (ja) * 2009-12-15 2011-06-23 タカラバイオ株式会社 アデノウイルスベクターの製造方法

Also Published As

Publication number Publication date
AU2002237910C1 (en) 2002-07-30
EP1363676B1 (en) 2007-03-28
US7534424B2 (en) 2009-05-19
CY1106676T1 (el) 2012-05-23
DK1363676T3 (da) 2007-07-23
WO2002056918B1 (en) 2004-04-08
ES2283524T3 (es) 2007-11-01
AU2002237910B2 (en) 2007-01-25
DE60219142D1 (de) 2007-05-10
CA2435443A1 (en) 2002-07-25
NZ527645A (en) 2008-10-31
EP1363676A2 (en) 2003-11-26
WO2002056918A2 (en) 2002-07-25
WO2002056918A3 (en) 2002-11-14
ATE357935T1 (de) 2007-04-15
US20040086486A1 (en) 2004-05-06
DE60219142T2 (de) 2007-12-13
PT1363676E (pt) 2007-06-22

Similar Documents

Publication Publication Date Title
Croyle et al. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver
Christ et al. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response
Nayerossadat et al. Viral and nonviral delivery systems for gene delivery
Sailaja et al. Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response
EP0787200B1 (en) Improved adenovirus and methods of use thereof
Koizumi et al. Reduction of natural adenovirus tropism to mouse Liverby Fiber-shaft exchange in combination with both CAR-Andαv integrin-BindingAblation
Chen et al. Effective repeat administration with adenovirus vectors to the muscle
Gill et al. The development of gene therapy for diseases of the lung
Wu et al. Cancer gene therapy by adenovirus-mediated gene transfer
JP2002516568A (ja) α−フェトタンパク質を発現する細胞に特異的なアデノウイルスベクターおよびその使用の方法
US5981275A (en) Transgene expression system for increased persistence
Guerette et al. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig
US6849446B2 (en) Modified bovine adenovirus having altered tropism
AU2001263689A1 (en) Modified bovine adenovirus having altered tropism
CA2341516A1 (en) Cationic complexes of polymer-modified adenovirus
US7534424B2 (en) Method of enhancing delivery of a therapeutic nucleic acid
AU2002237910A1 (en) Method of enhancing delivery of a therapeutic nucleic acid
EP1829555A2 (en) Method of enhancing delivery of a therapeutic nucleic acid
Connelly Adenoviral vectors
US20030223962A1 (en) Delivery of gene products to the lung parenchyma via gene transfer to the pleura
Denby et al. 127. Adenovirus type 5 vectors pseudotyped with fibers from subgroup D (19p and 37) show detargeting from hepatocytes in vitro and in vivo
Roy et al. 128. Use of chimeric adenoviral vectors to assess capsid neutralization determinants
AU3142902A (en) Novel transgene expression system for increased persistence

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080904

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081001

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090327